Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

Table 3 Characterization of potential 42 NAr mutation from treatment naive Korean patients of genotype C2 infections

Category	Mutation	Drug resistance	CH	HCC	P value
Primary drug resistance	T184A/C/F	ETV	1	-	0.021
	M204I/V	LMV, ETV, TNF	-	9
Mutation number (%)/no. of patients number			1/472 (0.21%)	9/576 (1.56%)
			1	9 patients
Secondary mutation	L80I	LMV	-	5	NS
	L180M	LMV, ETV, LdT	1	2
Mutation number (%)/no. of patients number			1/177 (0.56%)	7/216 (3.24%)
			1	6
Putative NAr mutation	S53N	LMV	1	1	N.S
	L82M/V	LMV	-	1
	V84M/I	ADV	1	-
	H126C/Y/Q	ADV	5	6
	I128I/N/A	LMV	11	5
	R/W153Q	LMV	2	-
	V191I/D	LMV, ADV	2	3
	V207I	LMV	-	1
	S213T	ADV	-	3
	Q215P/S/H	LMV, ADV	-	2
	L217R	ADV	1	-
	F221Y	ADV	3	9
	L229G/V/W	LMV	-	2
	P237H	ADV	-	2
	N238D/S/T	ADV	3	6
Mutation number (%)/no. of patients number			29/1475 (1.96%)	41/1800 (2.27%)
			23	31
Pre-treatment mutation	T38A		9	5	NS
	Y124H	Found	4	6
	D134E/N/C	Before	4	8
	N139K/H	Therapy	-	8
	I224V		4	12
Mutation number (%)/no. of patients number			21/351 (5.93%)	39/432 (9.02%)
			17	31
Total Mutation number (%)/no. of patients (%)			52/2478 (2.09)	96/3024 (3.17)	0.003
			32 patients (54.2)	47 patients (65.2)
			148/5502 (2.68)
			79 (60.3)

ETV: Entecavir; LMV: Lamivudine; TNF: Tenofovir; ADV: Adefovir; CH: Chronic hepatitis; HCC: Hepatocellular carcinoma.